Fierce Biotech

FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions

Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...

TheWell Bioscience Unveils RocketCell(TM) 3D iPSC Xeno-Free Complete Growth Kit: A Comprehensive Xeno-Free Ecosystem for Scalable iPSC Expansion

Alongside the complete kit, TheWell Bioscience has released the RocketCell (TM) iPSC Xeno-Free Growth Medium. Available as a standalone product, this xeno-free medium is designed for researchers who ...
PharmaTimes

Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...
Business Wire

Cellistic Reveals Groundbreaking iPSC-based Platforms to Accelerate Off-the-shelf Allogeneic Cell Therapy Development and Manufacturing

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...
American Association of Individual Investors

Why Century Therapeutics, Inc.’s (IPSC) Stock Is Up 30.65%

As of Thursday, January 08, Century Therapeutics, Inc.’s IPSC share price has surged by 30.65%, which has investors ...

TheWell Bioscience Unveils RocketCell™ 3D iPSC Xeno-Free Complete Growth Kit: A Comprehensive Xeno-Free Ecosystem for Scalable iPSC Expansion

TheWell Bioscience is proud to announce the commercial launch of its new RocketCell™ product line, introducing two cutting-edge solutions for stem cell research: the RocketCell™ 3D iPSC Xeno-Free ...